Cytarabine and daunorubicin liposomal (Vyxeos)

Mechanism of action

This drug is a liposomal formulation of Cytarabine (Ara-C) and Daunorubicin (Cerubidine) in a 5:1 molar ratio.
Route: IV
Extravasation: no information

Disease for which it is used

• Acute myeloid leukemia

History of changes in FDA indication

• 8/3/2017: Granted FDA regular approval for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC), two types of AML having a poor prognosis. (Based on CLTR0310-301)

History of changes in EMA indication

• 8/23/2018: Initial authorization

Patient Information

• Cytarabine and daunorubicin liposomal (Vyxeos) package insert

Also known as

• Code name: CPX-351
• Brand name: Vyxeos, Vyxeos liposomal